1. US Food & Drug Administration. FDA approves tucatinib for patients with HER2-positive metastatic breast cancer [media release]. 2 Jun 2020.
https://www.fda.gov/
.
2. Seattle Genetics. Seattle Genetics announces the approval of TUKYSA™ (tucatinib) in Switzerland for the treatment of patients with metastatic HER2-positive breast cancer [media release]. 28 May 2020.
3. Seattle Genetics. EMA validates Seattle Genetics Marketing Authorization Application for tucatinib for patients with locally advanced or metastatic HER2-positive breast cancer [media release]. 31 Jan 2020.
4. Kulukian A, Lee P, Taylor J, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976–87.
5. Oncothyreon. Oncothyreon announces corporate name change to Cascadian Therapeutics (NASDAQ: CASC) [media release]. 18 Jun 2016.